Alliances

Found 54,363 articles

• enGene, Inc. and Forbion European Acquisition Corp. (“FEAC”, Nasdaq: FRBN) Announce Business Combination Agreement to Create Nasdaq-Listed Biotechnology Company

  5/17/2023

  enGene, Inc. and Forbion European Acquisition Corp. today announced that they have entered into a definitive business combination agreement.

• Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission

  5/17/2023

  Motus GI Holdings, Inc. today announced in collaboration with the Ecuadorian Institute of Digestive Diseases (IECED) initiation of a clinical evaluation of the Pure-Vu Gen 4 Gastro, which is designed for upper gastrointestinal (GI) bleeding procedures - an area of high unmet patient need.

• Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™

  5/17/2023

  Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical Food.

• Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer

  5/17/2023

  Aitia, the leader in the development and application of Causal AI and "Digital Twins" to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer.

• Closed Loop Medicine and Pharmanovia enter a co-development partnership for precision medicine combination therapeutics

  5/17/2023

  Closed Loop Medicine Ltd and Pharmanovia today announced that they have entered a global co-development partnership.

• Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC

  5/17/2023

  Spanish biopharmaceutical company Biofabri, a subsidiary of Zendal, and IAVI, an international nonprofit research organization focused on developing vaccines and antibodies against infectious and neglected diseases, today announced the signing of an agreement for end-to-end development of the tuberculosis (TB) vaccine candidate MTBVAC.

• Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

  5/17/2023

  Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

  5/17/2023

  Eterna Therapeutics Inc. and Factor Bioscience will present eight poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.

• 

  Astellas, Sony Team on Novel ADC Platform for Oncology

  5/16/2023

  A collaborative research agreement will leverage Sony’s unique polymer, which the companies contend is a stable, effective linker for delivering antibody-drug conjugate payloads to cancer cells.

• Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease

  5/16/2023

  Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need.

• Labcorp and Providence Expand Strategic Laboratory Relationship

  5/16/2023

  Labcorp, a leading global life sciences company, announced it entered into an agreement with Providence to expand the longstanding strategic relationship between the two organizations.

• Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda®

  5/16/2023

  Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda ® in Patients with Advanced Refractory Melanoma at Duke Cancer Institute.

• Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection for the Treatment of T-cell Leukemia Across the United States

  5/16/2023

  Shorla Oncology today announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

• Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

  5/16/2023

  Personalis, Inc., National Cancer Center, and Ono Pharmaceutical Co., Ltd. announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.

• ValGenesis and KVS Technologies Partner to Drive Digital Transformation Across Multiple Industry Processes

  5/16/2023

  ValGenesis, Inc. and KVS Technologies have partnered to drive digital transformation across clinical research organizations (CRO) and pharmaceutical, healthcare, medical device, OEM machine manufacturing, enterprise resource planning (ERP), and information technology (IT) companies.  

• Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

  5/16/2023

  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX) today announced positive top-line results from its Phase 2b clinical trial of VK2809, a novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH).

• QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®

  5/16/2023

  QSAM Biosciences, Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., announced today a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam® (Samarium-153 DOTMP).

• Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts

  5/16/2023

  Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).

• Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases

  5/16/2023

  Scribe Therapeutics Inc. today announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

• Adolore Biotherapeutics Enters Exclusive License Agreement with University of Miami for Patents Protecting Non-Enzymatic Carbonic Anhydrase DNA Constructs and Their Protein Products and Uses

  5/16/2023

  Adolore Biotherapeutics, Inc. ("Adolore" or the "Company") today announced it has entered into an exclusive licensing agreement with the University of Miami (or the "University") for its intellectual property portfolio entitled "Long Acting Local Analgesic" and "Long Acting Local Analgesic Mechanisms."